> top > projects > sentences > docs > PubMed:12560435 > annotations
sentences Home  

PubMed:12560435 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-90 Sentence denotes HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.
T1 0-90 Sentence denotes HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.
TextSentencer_T2 91-99 Sentence denotes PURPOSE:
T2 91-99 Sentence denotes PURPOSE:
TextSentencer_T3 100-273 Sentence denotes Human epidermal growth factor receptor 2 (HER2) overexpression was found to predict a good response in breast carcinoma patients treated with doxorubicin (Adriamycin [ADM]).
T3 100-273 Sentence denotes Human epidermal growth factor receptor 2 (HER2) overexpression was found to predict a good response in breast carcinoma patients treated with doxorubicin (Adriamycin [ADM]).
TextSentencer_T4 274-435 Sentence denotes Evidence from our recent study indicates that node-positive patients respond to cyclophosphamide, methotrexate, and fluorouracil (CMF) regardless of HER2 status.
T4 274-435 Sentence denotes Evidence from our recent study indicates that node-positive patients respond to cyclophosphamide, methotrexate, and fluorouracil (CMF) regardless of HER2 status.
TextSentencer_T5 436-663 Sentence denotes We address the issue of whether therapy regimens including CMF and ADM versus CMF alone have the same therapeutic effect in patients with HER2+ and HER2- tumors in terms of relapse-free survival (RFS) and overall survival (OS).
T5 436-663 Sentence denotes We address the issue of whether therapy regimens including CMF and ADM versus CMF alone have the same therapeutic effect in patients with HER2+ and HER2- tumors in terms of relapse-free survival (RFS) and overall survival (OS).
TextSentencer_T6 664-672 Sentence denotes METHODS:
T6 664-672 Sentence denotes METHODS:
TextSentencer_T7 673-821 Sentence denotes Archival specimens of the primary tumors from 506 patients in a prospective clinical trial were stained with the anti-HER2 monoclonal antibody CB11.
T7 673-821 Sentence denotes Archival specimens of the primary tumors from 506 patients in a prospective clinical trial were stained with the anti-HER2 monoclonal antibody CB11.
TextSentencer_T8 822-983 Sentence denotes Originally, patients were randomly allocated to receive either 12 courses of intravenous CMF or eight courses of the same regimen followed by four cycles of ADM.
T8 822-983 Sentence denotes Originally, patients were randomly allocated to receive either 12 courses of intravenous CMF or eight courses of the same regimen followed by four cycles of ADM.
TextSentencer_T9 984-1198 Sentence denotes RFS and OS were analyzed by a Cox model taking into account treatment, HER2 status, and the interaction between treatment and HER2 status, adjusting for the effect of other known clinical and biopathologic factors.
T9 984-1198 Sentence denotes RFS and OS were analyzed by a Cox model taking into account treatment, HER2 status, and the interaction between treatment and HER2 status, adjusting for the effect of other known clinical and biopathologic factors.
TextSentencer_T10 1199-1207 Sentence denotes RESULTS:
T10 1199-1207 Sentence denotes RESULTS:
TextSentencer_T11 1208-1338 Sentence denotes Analysis of survival rates indicates a possible differential effect of treatment in the patients grouped according to HER2 status.
T11 1208-1338 Sentence denotes Analysis of survival rates indicates a possible differential effect of treatment in the patients grouped according to HER2 status.
TextSentencer_T12 1339-1446 Sentence denotes Improved RFS and OS were observed in the HER2+ subgroup after treatment with CMF plus ADM versus CMF alone.
T12 1339-1446 Sentence denotes Improved RFS and OS were observed in the HER2+ subgroup after treatment with CMF plus ADM versus CMF alone.
TextSentencer_T13 1447-1564 Sentence denotes With a median follow-up of 15 years, the hazard ratio (HR) for RFS was 0.83 in HER2+ tumors and 1.22 in HER2- tumors.
T13 1447-1564 Sentence denotes With a median follow-up of 15 years, the hazard ratio (HR) for RFS was 0.83 in HER2+ tumors and 1.22 in HER2- tumors.
TextSentencer_T14 1565-1695 Sentence denotes The effect of treatment was more evident on OS in HER2+ patients (HR = 0.61; CI, 0.32 to 1.16) than in HER2- patients (HR = 1.26).
T14 1565-1695 Sentence denotes The effect of treatment was more evident on OS in HER2+ patients (HR = 0.61; CI, 0.32 to 1.16) than in HER2- patients (HR = 1.26).
TextSentencer_T15 1696-1707 Sentence denotes CONCLUSION:
T15 1696-1707 Sentence denotes CONCLUSION:
TextSentencer_T16 1708-1800 Sentence denotes Our data indicate that adding ADM to CMF might be beneficial for patients with HER2+ tumors.
T16 1708-1800 Sentence denotes Our data indicate that adding ADM to CMF might be beneficial for patients with HER2+ tumors.